Agios ends development of tebapivat in low-risk MDS following subpar results
Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruvate kinase activator, known as tebapivat, did ...
May 29, 2026 10:50 AM EDT R&D Agios ends development of tebapivat in low-risk MDS following subpar results Ayisha Sharma News Reporter Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that